90Y radioembolization lung shunt fraction in primary and metastatic liver cancer as a biomarker for survival

Clinical Nuclear Medicine

Volumn 41, Issue 1, 2016, Pages 21-27

  Xing, Minzhi ^a   Lahti, Steven ^a   Kokabi, Nima ^b   Schuster, David M ^b   Camacho, Juan C ^b   Kim, Hyun S ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

90Y radioembolization; colorectal liver metastases; hepatocellular carcinoma; hepatopulmonary shunt fraction; intrahepatic cholangiocarcinoma; melanoma liver metastases; neuroendocrine tumor liver metastases

Indexed keywords

BIOLOGICAL MARKER; YTTRIUM 90; MACROSALB TC 99M; YTTRIUM;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; LUNG SCINTISCANNING; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS CANCER; PRIMARY TUMOR; PROPER HEPATIC ARTERY; PULMONARY SHUNT; RADIOEMBOLIZATION; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; AGED; ARTIFICIAL EMBOLIZATION; BILE DUCT TUMOR; COLORECTAL TUMOR; INTRAHEPATIC BILE DUCT; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LUNG; LUNG TUMOR; LUNG VENTILATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; SCINTISCANNING; SECONDARY; TUMOR VOLUME;

AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOMARKERS; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PULMONARY VENTILATION; RETROSPECTIVE STUDIES; TECHNETIUM TC 99M AGGREGATED ALBUMIN; TUMOR BURDEN; YTTRIUM RADIOISOTOPES;

EID: 84951111165     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000915     Document Type: Article

References (22)

1. El-Serag HB, Marrero JA, Rudolph L, Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008; 134: 1752-1763
2. Memon K, Lewandowski RJ, Kulik L, Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011; 21: 294-302
3. Martin LK, Cucci A, Wei L, Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. Clin Colorectal Cancer. 2012; 11: 195-199
4. Inarrairaegui M, Martinez-Cuesta A, Rodriguez M, Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2010; 77: 1441-1448
5. Kennedy A, Coldwell D, Sangro B, Radioembolization for the treatment of liver tumors general principles. Am J Clin Oncol. 2012; 35: 91-99
6. Owen JL, Mohamadzadeh M,. Macrophages and chemokines as mediators of angiogenesis. Front Physiol. 2013; 4: 159
7. Holash J, Maisonpierre PC, Compton D, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999; 284: 1994-1998
8. Gaba RC, Zivin SP, Dikopf MS, Characteristics of primary and secondary hepatic malignancies associated with hepatopulmonary shunting. Radiology. 2014; 271: 602-612
9. Salem R, Parikh P, Atassi B, Incidence of radiation pneumonitis after hepatic intra-Arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008; 31: 431-438
10. Salem ME, Jain N, Dyson G, Radiographic parameters in predicting outcome of patients with hepatocellular carcinoma treated with yttrium-90 microsphere radioembolization. ISRN Oncol. 2013; 2013: 538376
11. Lewandowski RJ, Sato KT, Atassi B, Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007; 30: 571-592
12. Salem R, Thurston KG,. Radioembolization with 90yttrium microspheres: a state-of-The-Art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006; 17: 1251-1278
13. Fleming CJ, Andrews JC, Wiseman GA, Hepatic vein tumor thrombus as a risk factor for excessive pulmonary deposition of microspheres during TheraSphere therapy for unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2009; 20: 1460-1463
14. Leung WT, Lau WY, Ho SK, Measuring lung shunting in hepatocellular carcinoma with intrahepatic-Arterial technetium-99 m macroaggregated albumin. J Nucl Med. 1994; 35: 70-73
15. Sato KT, Omary RA, Takehana C, The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol. 2009; 20: 1564-1569
16. Ho S, Lau WY, Leung WT, Arteriovenous shunts in patients with hepatic tumors. J Nucl Med. 1997; 38: 1201-1205
17. Schulze K, Gasch C, Staufer K, Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer. 2013; 133: 2165-2171
18. Urosevic J, Garcia-Albeniz X, Planet E, Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat Cell Biol. 2014; 16: 685-694
19. Theysohn JM, Schlaak JF, Muller S, Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration. J Vasc Interv Radiol. 2012; 23: 949-952
20. ACR-SIR practice parameter for radioembolization with microsphere brachytherapy device (RMBD) for treatment of liver malignancies. 2014 (Resolution 17). Available at: http://www.acr.org/∼/media/d8086059b5f541e9b64e55d68a71693b.pdf. Accessed April 15, 2015
21. Kennedy A, Nag S, Salem R, Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007; 68: 13-23
22. Tamrazi A, Lam MG, Louie JD, Management of high hepatopulmonary shunt fractions in patients undergoing radioembolization. J Vasc Interv Radiol. 2013; 24: S154